Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Thursday

Key Points

• Trevi Therapeutics is set to release its Q2 2025 earnings before market opens on August 7, with analysts predicting a loss of ($0.10) per share.
• The company reported a loss of ($0.09) EPS in the previous quarter, surpassing expectations of a loss of ($0.13) EPS.
• Institutional investors own 95.76% of the company's stock, with notable increases in stakes from firms such as Millennium Management LLC, which boosted its holdings by 356.3%.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Trevi Therapeutics to post earnings of ($0.10) per share for the quarter.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.04. On average, analysts expect Trevi Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Trevi Therapeutics Price Performance

Shares of TRVI traded down $0.03 during mid-day trading on Tuesday, reaching $7.46. The company's stock had a trading volume of 202,212 shares, compared to its average volume of 1,843,247. The company's 50 day moving average is $6.50 and its 200 day moving average is $5.84. Trevi Therapeutics has a 12-month low of $2.36 and a 12-month high of $8.11. The stock has a market cap of $874.75 million, a PE ratio of -16.57 and a beta of 0.58.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TRVI. Strs Ohio purchased a new position in Trevi Therapeutics during the 1st quarter valued at about $52,000. Millennium Management LLC lifted its position in Trevi Therapeutics by 356.3% during the first quarter. Millennium Management LLC now owns 823,249 shares of the company's stock valued at $5,178,000 after buying an additional 642,830 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Trevi Therapeutics by 31.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company's stock worth $278,000 after buying an additional 10,445 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Trevi Therapeutics by 20.4% in the first quarter. AQR Capital Management LLC now owns 27,720 shares of the company's stock worth $174,000 after purchasing an additional 4,688 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on TRVI shares. Wall Street Zen lowered shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Oppenheimer restated an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. D. Boral Capital reaffirmed a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a report on Monday, June 2nd. Cantor Fitzgerald began coverage on Trevi Therapeutics in a report on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 price objective for the company. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $24.00 price objective on shares of Trevi Therapeutics in a report on Tuesday, May 20th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $20.88.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.